Enlivex bets big on crypto prediction markets while advancing osteoarthritis therapy
Enlivex Therapeutics Ltd. is blending biotech with blockchain.
- Enlivex Therapeutics raised $212 million through a private equity deal and is using much of it to build a digital asset treasury via the RAIN token, a decentralized prediction market protocol.
- The company holds roughly 76 billion RAIN tokens and an option to buy nearly $918 million more at a deep discount, which analysts say could create a major unpriced value driver.
- Meanwhile, its osteoarthritis therapy Allocetra continues to show promising results in clinical trials. HC Wainwright reaffirmed a Buy rating on Enlivex and raised its 12-month price target to $13, citing both the RAIN token strategy and clinical progress.
The clinical-stage company, known for its osteoarthritis drug Allocetra, last year raised $212 million in a private equity deal and is now deploying a large portion of the proceeds to build a digital asset treasury anchored in prediction markets.
The move centers on the RAIN token, a fully decentralized prediction and options protocol on the Arbitrum network. Enlivex purchased 212 million RAIN tokens at $1 per share, funded in a mix of U.S. dollars and USDT, using them to implement what the company calls its first RAIN token treasury strategy.
The RAIN platform allows anyone to create and trade custom markets, with outcomes resolved via AI and governed by a deflationary buy-and-burn token mechanism.
RAIN undervalued
HC Wainwright & Co.’s Raghuram Selvaraju flagged the token as undervalued, noting that Enlivex’s holdings of roughly 76 billion RAIN tokens—plus an option to buy nearly $918 million more at $0.0033 per token—could create a future value driver currently unpriced by the market.
Since its launch in September 2025, RAIN has seen $1.5 billion in trading volume over 3.5 months, with daily volumes averaging $55 million. Analysts cite precedent projects such as Polymarket and Kalshi, which reached an $11 billion valuation, as evidence of the growth potential in decentralized prediction markets.
Enlivex isn’t leaving its biotech ambitions behind. Allocetra continues to show promising results in osteoarthritis trials, with six-month data demonstrating substantial pain reduction and functional improvement in patients aged 60 and older. Additional studies in basal thumb osteoarthritis are expected to report top-line results in the coming months.
HC Wainwright reiterated a Buy rating on Enlivex, raising its 12-month price target to $13 per share, citing both the potential of the RAIN token treasury and ongoing clinical progress with Allocetra.
